THE long-awaited new Hepatitis C drug will be available on Spain’s
national health system shortly, but only for certain patients.
to Dr María Londoño from the Hospital Clínic in Barcelona, a member of
the Spanish Agency for Medication and Healthcare Products, the drug
Sovaldi will be administered to sufferers awaiting a liver transplant or
who have undergone one, those with liver cirrhosis, or who have found
more traditional treatment to have been ineffective.
Those with minor fibrosis – which accounts for the majority of Hepatitis C sufferers – will not be given the new drug.